ContributorsPublishersAdvertisers

#Cll

ajmc.com

MRD Kinetics Identify High-Risk CLL in Study of Zanubrutinib, Venetoclax, Obinutuzumab

An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment duration. Findings from an abstract presented at the 2021 American Society of Hematology Meeting & Exposition suggest that...
Picture for MRD Kinetics Identify High-Risk CLL in Study of Zanubrutinib, Venetoclax, Obinutuzumab
onclive.com

Intensive Chemotherapy Falls a Few Steps Behind in Leukemia and Lymphoma

Naval Daver, MD, discusses the latest developments in acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and follicular lymphoma. The management of acute and chronic leukemias and lymphoma is becoming less reliant on intensive chemotherapy, explained Naval Daver, MD, who added that this paradigm shift has reflected a greater dependence instead on antibody-drug conjugates, BTK inhibitors, and FLT3/IDH inhibitors.
Picture for Intensive Chemotherapy Falls a Few Steps Behind in Leukemia and Lymphoma
srnnews.com

Gilead withdraws use of Zydelig to treat two types of cancer

(Reuters) – Gilead Sciences Inc on Friday notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer – follicular lymphoma and small lymphocytic leukemia. The U.S. Food and Drug Administration gave the drug an accelerated approval...
Picture for Gilead withdraws use of Zydelig to treat two types of cancer
TRENDING TOPICS
onclive.com

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

Anthony Mato, MD, discusses updated efficacy and safety results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor, pirtobrutinib, in patients with previously treated CLL/SLL that was presented at the American Society of Hematology 2021 Annual Meeting. Anthony Mato, MD, discusses data from the following presentation:. Updated results...
onclive.com

Subcutaneous Epcoritamab Demonstrates Early Activity, Favorable Tolerability in CLL

Subcutaneous epcoritamab demonstrated early activity and favorable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia and high-risk features. Subcutaneous epcoritamab demonstrated early activity and favorable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and high-risk features, according to preliminary results from the EPCORE CLL-1 trial (NCT04623541), presented during the 2021 ASH Annual Meeting.1.
onclive.com

Ibrutinib Increases Risk of Select Cardiovascular AEs in Patients With Chronic Lymphocytic Leukemia

Treatment with ibrutinib in patients with chronic lymphocytic leukemia was linked with increased risk of cardiovascular adverse effects like atrial fibrillation, hospital-diagnosed bleeding, and heart failure, but was not linked with a higher risk of acute myocardial infarction or stroke. Treatment with ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia...

Vectoring In On Verastem

Today, we take our first look at a small oncology firm called Verastem Oncology for the first time since late 2020. Never attribute to malice that which is adequately explained by stupidity."― Robert J. Hanlon. It has been just over a year since we last did an in-depth look...
MEDICAL & BIOTECH
cancernetwork.com

First-Line Targeted Treatment Approach Appears Efficacious for Older CLL Population

A pooled analysis indicated that patients who were 80 years or older had efficacious responses to targeted therapies for chronic lymphocytic leukemia regardless of coexisting conditions and organ dysfunction. Patients 80 years or older with chronic lymphocytic leukemia who received treatment with a targeted therapy experienced benefit regardless of the...
onclive.com

Zanubrutinib Improves PFS in Treatment-Naïve CLL/SLL

Zanubrutinib elicited a statistically significant improvement in progression-free survival vs the combination of bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma. Zanubrutinib (Brukinsa) elicited a statistically significant improvement in progression-free survival (PFS) vs the combination of bendamustine and rituximab (Rituxan; BR) in patients...
onclive.com

Dr. Danilov on the Reduced Use of Chemoimmunotherapy in CLL

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia. Alexey V. Danilov, MD, PhD, associate director, Toni Stephenson Lymphoma Center and professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.
shawnee.edu

Shawnee State University offering group fitness classes for adults

Shawnee State University’s Center for Lifelong Learning (CLL) is now offering adult group fitness classes in the James A. Rhodes Athletic Center. Classes are available weekly between Jan. 10 – Apr. 29. Classes include Karate, Yoga, Beginning Golf, Intermediate Golf, Soccer, Beginning Tennis, Weight Training, Step Fusion, and Pilates. Classes start at $4 per session and registration can be completed at shawnee.edu/group-fitness.
gilead.com

Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia

– In 2014, Zydelig® (idelalisib) received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic leukemia (SLL). Approval was based on a Phase 2 study in indolent non-Hodgkin lymphoma showing that 54% of those with FL and 58% of those with SLL had an objective response as assessed by an Independent Review Committee.
dana-farber.org

Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia

Adding the BCL-2 inhibitor drug venetoclax to a combination chemotherapy regimen significantly improved outcomes in Richter’s syndrome, a rare but deadly complication that develops in some patients with chronic lymphocytic leukemia (CLL), according to a study led by Dana-Farber investigators. The addition of the targeted drug venetoclax to a...
onclive.com

Incorporation of Chemotherapy-Free Regimens Improve Outcomes in Hematologic Malignancies

Thomas Kipps, MD, PhD, discussed navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS. The advent of novel targeted therapies, such as BTK inhibitors, antibody-drug conjugates (ADC), TKIs, and JAK inhibitors,...
YOU MAY ALSO LIKE